Hangzhou Alltest Biotech Co., Ltd.

Shanghai Stock Exchange 688606.SS

Hangzhou Alltest Biotech Co., Ltd. Free Cash Flow for the year ending December 31, 2023: USD -71.65 M

Hangzhou Alltest Biotech Co., Ltd. Free Cash Flow is USD -71.65 M for the year ending December 31, 2023, a -145.35% change year over year. Free cash flow is the amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.

Hangzhou Alltest Biotech Co., Ltd. Free Cash Flow for the year ending December 31, 2022 was USD 158.02 M, a 28.11% change year over year.
Hangzhou Alltest Biotech Co., Ltd. Free Cash Flow for the year ending December 31, 2021 was USD 123.35 M, a 37.49% change year over year.
Hangzhou Alltest Biotech Co., Ltd. Free Cash Flow for the year ending December 31, 2020 was USD 89.72 M, a 717.27% change year over year.
Hangzhou Alltest Biotech Co., Ltd. Free Cash Flow for the year ending December 31, 2019 was USD 10.98 M, a 570.08% change year over year.

Key data

Date	Free Cash Flow	Operating Cash Flow	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities

Shanghai Stock Exchange: 688606.SS

Hangzhou Alltest Biotech Co., Ltd.

CEO	Mr. Fei Gao
IPO Date	March 25, 2021
Location	China
Headquarters	#550, Yinhai Street
Employees	1,093
Sector	Health Care
Industries Biotechnology Chemicals & Advanced Materials Pharmaceuticals

Description

Hangzhou Alltest Biotech Co., Ltd. engages in the research, development, production, and market of in vitro diagnostic reagents worldwide. It offers rapid diagnostic products, including women's health, infectious diseases, drugs, cancer, cardiovascular, and other five series of products. The company is based in Hangzhou, China.

Key trends

Past 5 years